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A comparison of the structure of ciprofloxacin and grepafloxacin shows that the two compounds are similar, with two 
exceptions: grepafloxacin has a methyl group at the 5 position and a methyl group attached to the 7-piperazinyl 
substituent. At the 1 position, both compounds have a cyclopropyl group, which is important for potency, but limits 
anaerobic activity. The methylpiperazine at position 7 in grepafloxacin is associated with its enhanced Gram-positive 
activity and long half-life. The methyl group at R5 is also thought to enhance Gram-positive activity. Ciprofloxacin‘s 
piperazine group at the 7 position is associated with good Gram-negative activity. Grepafloxacin’s Gram-negative activity 
is comparable to that of ciprofloxacin’s against Haernophilus influenzae, Moraxella catarrhalisand enteric Gram-negative 
bacilli. 
Studies of resistance development to fluoroquinolones suggest that grepafloxacin is associated with a reduced selection 
of resistance in Staphylococcus aureus, which is possibly related to the inhibition or avoidance of efflux transport by 
NorA. 
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STRUCTURE-ACTIVITY 
There are currently seven fluoroquinolones available in 
the USA and nine in Europe. They all have similar 
basic structures, but differ in substituents in positions 1, 
5, 7 and 8. 
The particular focus of this paper is the structure- 
activity relationships that relate to grepafloxacin. A 
comparison of ciprofloxacin and grepafloxacin shows 
that the two compounds are similar, with two 
exceptions: grepafloxacin has a methyl group at the 
5 position and a methyl group attached to the 7- 
piperazinyl substituent [l]. In contrast, ciprofloxacin 
has a hydrogen group at the 5 position and attached 
to the piperazinyl substituent. The cyclopropyl group 
is retained at the 1 position in both compounds. 
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Structureactivity relationships have been developed 
for a large number of quinolone congeners [2]. 
Positions 1 and 8 on the quinolone molecule 
At position 1 of the quinolone molecule, there is a 
cyclopropyl group in ciprofloxacin that is retained in 
grepafloxacin (Figure 1). For activity, the cyclopropyl 
group appears to be the most potent of a large number 
of additional substituents. The X8 position is important 
for anaerobic activity. Both ciprofloxacin and grepa- 
floxacin have carbon and hydrogen groups in this 
position, whch results in relatively limited anaerobic 
activity. 
Substituents at position 7 
The most common substituent at the 7 position is a 
piperazine or an alkyl-substituted piperazine. Cipro- 
floxacin has a piperazine and grepafloxacin has a 
methylpiperazine at this position. The methyl group 
has been associated with enhanced Gram-positive 
activity, and accounts, in part, for the enhanced Gram- 
positive activity of grepafloxacin [2]. In addition, this 
substituent lengthens the serum half-life, making it 
easier to administer such compounds less frequently [2]. 
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Figure 1 The structure-activity relationships of fluoroquinolones. Reproduced with kind permission of the Oxford 
University Press, from Domegla [2]). 
Grepafloxacin’s activity against a methicillin-suscep- 
tible Staphylococcus aureus strain is enhanced by almost 
an order of magnitude compared with ciprofloxacin 
and ofloxacin [3,4]. It is noteworthy, however, that 
with methicillin-resistant strains of Staphylococcus aureus, 
which epidemiologically have now acquired substantial 
levels of ciprofloxacin resistance, there is some degree 
of cross-resistance with grepafloxacin and other quino- 
lones [ 5 ] .  Certainly, those strains with the highest level 
of ciprofloxacin resistance are not likely to be susceptible 
to grepafloxacin or most other quinolones. 
The piperazine group, relative to some other sub- 
stituents, retains the best Gram-negative activity [2]. 
Grepafloxacin has good activity against Gram-negative 
bacteria, such as Haemophilus injuenzae [1,5,6]. The 
spectrum of grepafloxacin’s Gram-negative activity 
includes Escherichia coli, Klebsieila pneumoniae and Entero- 
bacter cloacae [3-51, against which activity is similar to 
that of ciprofloxacin, and Pseudomonas aeruginosa, 
against which activity is diminished about four-fold 
relative to ciprofloxacin [ 11. 
R5 position 
The R5 position also relates to both structure-activity 
and potency [ 2 ] .  Grepafloxacin has a methyl group 
and ciprofloxacin a hydrogen group in this position. 
The methyl substituent enhances Gram-positive activity. 
Sparfloxacin has, at this position, an amino group, 
which enhances its Gram-positive activity. The com- 
bination of the two methyl groups in grepafloxacin 
seems to account, at least in part, for its enhanced 
Gram-positive activity, including enhanced activity 
against Streptococcus pneumoniae [2]. 
BACTERIAL DNA TOPOISOMERASES 
Fluoroquinolones clearly interact with bacterial type 
I1 DNA topoisomerases. The original identification 
of the principal target in Gram-negative bacteria as 
DNA gyrase was made over a decade after nalidixic 
acid, the first quinolone, was introduced into clinical 
use [7, 81. It has been recognized more recently that 
there is another topoisomerase within bacterial cells 
(topoisomerase IV) that is similar to DNA gyrase [9]. 
DNA gyrase has a tetrameric structure with two A 
and two B subunits. The more recently recognized 
enzyme topoisomerase IV is similar to DNA gyrase in 
terms of its subunit structure [10,11]. Topoisomerase 
IV is a heterotetramer with two ParC and two ParE 
subunits, which in Staphylococcus aureus are referred 
to as GrlA and GrlB, respectively. Both of these 
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enzymes are essential to the bacterial cell. DNA gyrase 
is involved in DNA supercoiling activity, and topoiso- 
merase IV in DNA decatenation to separate replicated, 
but interlinked daughter chromosomes into daughter 
cells. There is also a striking homology between 
the subunits of the two enzymes. GyrA is homologous 
to ParC (36% amino-acid identity), and GyrB is 
homologous to ParE (40% amino acid identity). 
In Staphylococcus aureus, we have selected strains for 
resistance to various quinolones, such as ciprofloxacin 
or ofloxacin (Table 1) [12-141. Certain of these mutants 
have single-step (first-step) mutations in GrlA of 
topoisomerase IV In this circumstance, relative to the 
parent strain, GrlA mutants exhibit an increase in 
resistance to ciprofloxacin and also, though somewhat 
less, to grepafloxacin. As these GrlA mutants resulted 
from a single mutational event in genetically defined 
strains, it suggests that, in Staphylococcus aureus [15], 
topoisomerase IV is the principal target for these 
quinolones rather than DNA gyrase. However, there 
are differences among the quinolones in terms of the 
topoisomerase that is the principal target in different 
cells. Pan and Fisher have shown that in Streptococcus 
pneumoniae the principal target of ciprofloxacin is 
topoisomerase IV but the principal target of spar- 
floxacin is DNA gyrase [16]. For Staphylococcus aureus, 
however, it appears that the principal target for 
grepafloxacin, as for ciprofloxacin, is topoisomerase IV 
An additional mutation in the GyrA subunit causes a 
hrther increase in resistance to ciprofloxacin as well as 
to grepafloxacin (Table 1). 
Many of the methicillin-resistant, ciprofloxacin- 
resistant clinical strains of Staphylococcus aureus have 
multiple mutations that account for the high level of 
resistance [17,18]. These organisms would be likely to 
exhibit cross-resistance for ciprofloxacin and grepa- 
floxacin. There are, however, some differences between 
grepafloxacin and ciprofloxacin in terms of other 
mechanisms of resistance. 
Table 1 Activity of grepafloxacin and ciprofloxacin against 
genetically defined strains of Staphylococcus aureus 
MIC (mg/L) 
Strain Genotype Grepdoxacin Ciprofloxacin 
ISP794 
ISP86 
MT23142 
MT42351 
MT5224c9 
MT5222 
EN1252 
MT1222 
0.125 
0.125 
0.125 
0.5 
0.5 
0.5 
16.0 
16.0 
0.25 
0.25 
1 .o 
2.0 
2.0 
2.0 
32.0 
64.0 
NorA resistance 
In defining our Staphylococcus aureus mutants, a strain 
was identified that hyperexpresses NorA [13], an active 
drug efflux pump. It was possible to manipulate this 
strain genetically so that it was identical to other 
strains except for a mutation in the promoter region of 
the norA gene called JqB, which is associated with 
hyperexpression of NorA [ 131. Hyperexpression of this 
NorA pump causes a four- to eight-fold increase in 
resistance to ciprofloxacin, but there is no effect of this 
mutation on resistance to grepafloxacin (Table 2) [19]. 
Pumps similar to NorA have been increasingly 
recognized, and they often occur in multiplicity (i.e. 
not a single pump, but multiple pumps for a given 
organism). In Gram-positive bacteria, various of these 
pumps occur in the cytoplasmic membrane [20]. 
In Gram-negative bacteria, pumps situated in the 
cytoplasmic membrane are also linked to the outer 
membrane for pumping drugs across both membranes 
In our laboratory, we have studied the effects of 
NorA on quinolone activity and have been able to 
prepare everted inner-membrane vesicles that contain 
hyperexpressed NorA [13]. We have shown that the 
uptake of radiolabeled norfloxacin is dependent on 
the presence of the NorA protein, and energy, and is 
also saturable, indicating a carrier-mediated transport 
process [ 131. 
Competition studies involving adding unlabeled 
ciprofloxacin or ofloxacin show that these drugs 
compete with norfloxacin for NorA transport [13]. 
The results correlate with the effects of NorA hyper- 
expression on activity for the different compounds. 
The effect of hyperexpressing NorA on sensitivity to 
norfloxacin is a 32-fold increase in resistance; the effect 
is less for ciprofloxacin (eight-fold) and ofloxacin 
(four-fold). These findings correlate with the affinity 
properties of the NorA efflux transporter, as measured 
in everted membrane vesicles, with an apparent K ,  
of 6 pM for norfloxacin, and apparent K, values of 
26 pM for ciprofloxacin and 50 pM for ofloxacin (Table 
3) [13]. These values give a rough rank order of the 
[21-231. 
Table 2 Effect of hyperexpression of n o d  on the activity 
of fluoroquinolones 
Quinolone Change in MICa 
Nodoxacin 
Ciprofloxacin 
Ofloxacin 
Grepdoxacin 
32-fold 
8-fold 
4-fold 
No change 
'MIC ratio =Escherichia coli DHlOB[pMTlOl (norA)]/ 
DHlOB[pUC 191. 
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apparent affinity of norfloxacin, ciprofloxacin and 
ofloxacin for the efflux transporter. 
In contrast, grepafloxacin behaves differently in 
that it inhibits transport of norfloxacin in these vesicles 
non-competitively [19]. Competitive inhibition implies 
that as concentrations of the norfloxacin substrate 
increase, the V,,, will not change in the presence 
of the inhibitor. In a number of experiments, 
grepafloxacin added in this system acted non- 
competitively by reducing the V,, [19]. This non- 
competitive inhibition of transport correlates to some 
extent with the lack of effect of hyperexpression of 
NorA on grepafloxacin activity. 
The effect of inhibition of NorA by other means 
has effects on the frequency with which resistance can 
be selected. Reserpine is an inhibitor of the NorA 
efflux pump, both in vesicles and for resistance 
associated with hyperexpression of NorA in whole cells 
[13,24]. The frequency of selection ofmutations can be 
estimated by plating Staphylococcus aureus cells on agar 
containing fluoroquinolones at  different concentrations 
and then counting the number of resistant colonies 
that arise. Plating of Staphylococcus aureus cells on agar 
containing norfloxacin at different concentrations with 
and without reserpine shows that reserpine, as a means 
of inhibiting efflux transport, reduces the frequency 
with which resistant mutants are selected (Table 4) [25]. 
The ability to block transport by NorA, or to be a poor 
substrate for NorA, may be advantageous in terms of 
the ease of selection of resistance, although other 
factors may also contribute. 
Table 3 Correlation of activity against NorA-mediated 
resistance and transport 
Effect Of NorA efflux transport 
on activity 
Quinolone (MIC increase) Km (pM) K, (pM) 
Norfloxacin x 32 6.0 - 
Ciprofloxacin X 8  - 26.4T4.4 
Ofloxacin x 4  - 50.5k9.6 
Reproduced with kind permission from the American Society for 
Microbiology, from Ng et al [13]. 
SELECTION OF MUTANTS 
Comparison of the ability of grepafloxacin and 
ciprofloxacin to select resistant mutants shows that 
frequencies of resistance are substantially less with 
grepafloxacin (Table 5). Selecting drug concentrations 
were adjusted for factor above MIC. At a grepafloxacin 
concentration of 0.5 mg/L, the frequency of resistance 
was undetectable when 10" cells were plated, whereas 
it was relatively easy to obtain mutants for cipro- 
floxacin, even at a concentration of 2 mg/L (Table 5). 
Ciprofloxacin concentration had to be increased to 8 
mg/L to get a simdarly low frequency. Compared to 
ciprofloxacin, frequencies of resistance were lower with 
grepafloxacin, perhaps because it is not affected by 
NorA, or perhaps because NorA expression is reduced 
or blocked in wild-type cells. 
SAFETY PROFILE 
Structure-safety relationships have been identified for 
some components of the safety profile of fluoro- 
quinolones. 
Theophylline interaction 
At the 1 position of the quinolone molecule, a 
cyclopropyl group is the most potent for activity, but 
this substituent has been associated with an interaction 
with theophylline [2]. This interaction, however, is 
more strongly affected by substituents at position 7. At 
t h s  position, methylpiperazine substituents as found in 
grepafloxacin reduce theophylline interactions because 
they have greater bulk than the piperazine substituents. 
Central nervous system toxicity 
At the 7 position, the presence of a piperazine group 
has been associated with two effects-central nervous 
system (CNS) toxicity and interaction with non- 
steroidal anti-inflammatory agents (NSAIDs) [ 2 ] .  In 
animal studies, binding of the inhibitory neuro- 
transmitter ?/-aminobutyric acid (GABA) to its receptor 
was inhibited by quinolones, an effect that may be 
enhanced by NSAIDs [26,27]. Methyl-substituted 
piperazines at  the 7 position, in comparison to an 
Table 4 Effect of reserpine on the frequency of norfloxacin-resistant Staphylococcus aureus. 
Number of resistant colomes at norfloxacin concentration fme/L) 
Condition 1.25 2.5 5.0 10 20 
No reserpine 1 508 173 48 29 0 
Reserpine (20 mg/L) 72 21 1 0 0 
Reproduced with land permission from the American Society for Microbiology, from Markham and Neyfakh 1251. 
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Table 5 Frequency of selection of single-step mutants of Staphylococrus aureus resistant to 
grepafloxacin and ciprofloxacin 
Selecting drug 
Grepafloxacin Ciprofloxacin 
Selecting drug 
concentration Factor above Mutation Factor above Mutation 
(mg/L) MIC kequency MIC frequency 
0.125 1 .0 TNTC 0.5 
0.25 2.0 8 x lo-* 1 .0 TNTC 
- 
0.5 4.0 < 9  ~ 1 0 . ~  2.0 2 x 10-5 
1 .0 8.0 < 9 x 10-9 4.0 8 x 10-7 
2.0 16.0 < 9 x 8.0 < 9 x 10-9 
TNTC, too numerous to count 
unsubstituted piperazine, may reduce both interactions 
with the GABA receptor and the enhancement of that 
interaction by NSAIDs. 
Phototoxicity 
At position 8, several substituents, particularly halides, 
have been associated with the greatest enhancement of 
phototoxicity, but the CH group present at this position 
in both ciprofloxacin and grepafloxacin does not appear 
to enhance phototoxic potential substantially [2]. A 
methoxy group at this position may further reduce 
phototoxic potential [28,29]. 
Data on structure-safety relationships suggest that 
a methyl group at position 5 as found in grepafloxacin 
may enhance phototoxicity, possibly through increasing 
concentrations in skin due to increased lipophilicity [2]. 
There may be less enhancement of phototoxicity from 
an amino substitution at this position [2]. 
Safety summary 
Grepafloxacin shows some interaction with theo- 
phylline, though it is not as great as that for cipro- 
floxacin. The interaction with NSAIDs in animal 
studies has been low, which would suggest that CNS 
toxicity may also be relatively low. The most photo- 
toxic marketed quinolones are lomefloxacin, spar- 
floxacin and fleroxacin, which have halide groups at the 
8 position. There is a relatively low level of phototoxic 
potential with grepafloxacin, comparable to that with 
ciprofloxacin, based on structuresafety predictions, 
and clinical studies have also supported a low level of 
phototoxicity for grepafloxacin (< 2.0%). 
Comparing ciprofloxacin and grepafloxacin, both 
have limited interactions with theophylline and relatively 
low phototoxic potential, but for grepafloxacin, inter- 
actions with NSAIDs are possibly reduced. 
CONCLUSIONS 
Compared with ciprofloxacin, grepafloxacin’s structure 
gives it enhanced activity against Gram-positive patho- 
gens and Mycoplasma, preserved activity against some 
of the Gram-negative bacilli, such as H. influenzae, 
Moraxella catarrhalis and many members of the Entero- 
bacteriaceae. There is, however, reduced activity against 
P aeruginosa. Grepafloxacin also has reduced selection 
of resistance in Staphylococcus aureus, which may be 
related to the ability of this fluoroquinolone to 
circumvent or block efflux transport by NorA. Pre- 
liminary data also suggest that efflux pumps like those 
in Staphylococcus aureus that may contribute to its 
resistance to many antibiotics will also be found in 
Streptococcus pneumoniae [30]. 
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